Our Investigational New Drug, MEB-1170, was approved by the FDA on October 6th, 2022 to enter Phase 1 human clinical trials.  MEB-1170 is being developed to treat opioid use disorder.  MEB-1170 shows no abuse potential in pre-clinical studies. We believe MEB-1170 holds the promise to solve the opioid crisis.

We have also been conducting a hit-to-lead discovery program targeting the Sphingosine-1 phosphate receptor (S1PR1) for the treatment of neuropathic pain and neuroinflammation.